Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

512.50 -0.75 (-0.15%)
Streaming Delayed Price Updated: 2:28 PM EDT, Sep 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
68 69 Next >
News headline image
My Top 5 Favorite Stocks for an Uncertain Market ↗
These players offer a certain level of stability in any market environment. 
Via The Motley Fool
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company’s... 
Via MarketBeat
News headline image
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality. 
Via The Motley Fool
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Brush Off
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
News headline image
Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a... 
Via MarketBeat
News headline image
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal... 
Via MarketBeat
News headline image
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD... 
Via StockStory
Topics Artificial Intelligence
News headline image
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock ↗
The company has tremendous prospects. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Why CRISPR Therapeutics Stock Rocked the Market Last Month ↗
The company had fallen out of investor favor; its recovery was impressive. 
Via The Motley Fool
News headline image
Where Will CRISPR Therapeutics Stock Be in 5 Years? ↗
CRISPR's expanding pipeline could unlock significantly more value by 2031. 
Via The Motley Fool
News headline image
3 Market-Beating Stocks for Long-Term Investors
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y... 
Via StockStory
News headline image
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗
They could both outperform the market over the medium term, but one appears to have a clear edge. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.61% on an annualized basis producing an average annual return of 14.84%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
News headline image
3 Stocks Whose Competitive Walls Tower Over Nvidia's ↗
A solid moat favors revenue growth, and that's good news for investors. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 ↗
We'll know a little more about the company's prospects by the end of the year. 
Via The Motley Fool
News headline image
1 S&P 500 Stock with Exciting Potential and 2 We Ignore
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Stocks
News headline image
If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.32% on an annualized basis producing an average annual return of 14.56%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
News headline image
2 Large-Cap Stocks to Research Further and 1 We Question
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m... 
Via StockStory
News headline image
Inflation Is Rising Again. History Says These 2 Stocks Are Among the Smartest Places to Hide ↗
Inflation affects corporations differently. These two have the tools to navigate the challenge better than most. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside? ↗
Vertex dominates cystic fibrosis and has a debt-free balance sheet, but can its pipeline restore faster growth? See why our analysts gave the stock a strong 7.3 out of 10. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? ↗
This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’ ↗
CNBC's Halftime Report Final Trades: Sechan picked ServiceNow (NYSE: NOW), Lebenthal chose Vertex (NASDAQ: VRTX) and Brown recommended Uber (NYSE: UBER). 
Via Benzinga
News headline image
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗
Don't bet against Vertex Pharmaceuticals in cystic fibrosis. 
Via The Motley Fool
News headline image
3 Cash-Producing Stocks on Our Watchlist
Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen ... 
Via StockStory
News headline image
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗
The drugmaker should significantly mitigate its most important risk as it develops new products. 
Via The Motley Fool
News headline image
$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.35% on an annualized basis producing an average annual return of 14.69%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
News headline image
Vertex (VRTX) Q2 2026 Earnings Call Transcript ↗
Revenue hit $3.3 billion with guidance raised on strong newer product growth. 
Via The Motley Fool
Topics Earnings
Discover which S&P500 stocks are making waves on Monday. ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
Get insights into the top movers in the S&P500 index of Monday's pre-market session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.